Literature DB >> 16731120

Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.

Jose M Clavero1, Claude Deschamps, Stephen D Cassivi, Mark S Allen, Francis C Nichols, Brigitte A Barrette, Dirk R Larson, Peter C Pairolero.   

Abstract

BACKGROUND: Little information is available regarding long-term survival after pulmonary metastasectomy for gynecologic malignancies.
METHODS: All patients who underwent pulmonary resection for gynecologic malignancies at our institution between January 1985 and June 2001 were reviewed. Factors affecting long-term survival were analyzed.
RESULTS: There were 103 patients, 70 of whom had metastatic disease limited to the lungs. Median age of these 70 patients was 59.4 years (range, 31 to 80 years). The primary tumor originated in the uterine corpus in 37 patients, endometrium in 23, cervix in 7, ovaries in 2, and vagina in 1. Histopathology was leiomyosarcoma in 29 patients, adenocarcinoma in 23, other sarcoma in 11, squamous cell carcinoma in 5, and choriocarcinoma and endolymphatic stromal myosis in 1 each. The median time interval between the first gynecologic procedure and pulmonary resection was 24 months (range, 0 to 237 months). A wedge excision was performed in 44 patients, lobectomy in 14, bilobectomy in 2, pneumonectomy in 1, and a combination in 9. Five patients (7%) had an incomplete resection. Eighteen patients (25.7%) developed at least one complication and 1 died (operative mortality, 1.4%). At last follow-up, 35 had died, and the median follow-up among those who were still alive was 36 months (range, 6 months to 13 years). Five-year and 10-year survival was 46.8% (95% confidence interval, 34.2% to 63.0%) and 34.3% (95% confidence interval, 19.7% to 52.5%), respectively. Factors that adversely affected survival include a disease-free interval between the first gynecologic procedure and pulmonary resection of less than 24 months (p = 0.004) and a primary site located in the cervix (p < 0.001).
CONCLUSIONS: Pulmonary resection for metastatic gynecologic cancer in selected patients is safe and effective. Both a short disease-free interval between the primary gynecologic procedure and pulmonary metastasectomy, and a primary cervical tumor had an adverse effect on survival.

Entities:  

Mesh:

Year:  2006        PMID: 16731120     DOI: 10.1016/j.athoracsur.2006.01.068

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  26 in total

Review 1.  Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.

Authors:  Martee L Hensley; Brigitte A Barrette; Klaus Baumann; David Gaffney; Anne L Hamilton; Jae-Weon Kim; Johanna U Maenpaa; Patricia Pautier; Nadeem Ahmad Siddiqui; Anneke M Westermann; Isabelle Ray-Coquard
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

Review 2.  The role of local therapy in the management of lung and liver oligometastases.

Authors:  Simon S Lo; Susan D Moffatt-Bruce; Laura A Dawson; Roderich E Schwarz; Bin S Teh; Nina A Mayr; Jiade J Lu; John C Grecula; Thomas E Olencki; Robert D Timmerman
Journal:  Nat Rev Clin Oncol       Date:  2011-05-24       Impact factor: 66.675

3.  Outcome of Radiation Therapy for Stage IVB Uterine Cervical Cancer With Distant Lymph Nodes Metastases; Sequential Irradiation for Distant Lymph Nodes Metastases.

Authors:  Yuki Mukai; Naho Ruiz Yokota; Madoka Sugiura; Taichi Mizushima; Risa Taniuchi; Yuichi Imai; Kotaro Hashimoto; Yuya Tabuchi; Etusko Miyagi; Masaharu Hata
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 4.  Pulmonary metastasectomy: an overview.

Authors:  Francesco Petrella; Cristina Diotti; Arianna Rimessi; Lorenzo Spaggiari
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 5.  Pulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors.

Authors:  Rocco Bilancia; Marco Nardini; David Waller
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

6.  Radiation Therapy for Uterine Cervical Cancer With Lung Metastases Including Oligometastases.

Authors:  Yuki Mukai; Izumi Koike; Tatsuya Matsunaga; Naho Ruiz Yokota; Syoko Takano; Madoka Sugiura; Mizuki Sato; Etsuko Miyagi; Masaharu Hata
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

7.  Role of metastasectomy and chemotherapy in carcinoma of uterine cervix.

Authors:  Nasir Ali; Muhammad Atif Mansha; Ahmed Nadeem Abbasi; Bilal Mazhar Qureshi
Journal:  BMJ Case Rep       Date:  2017-08-02

Review 8.  The role of adjuvant therapy in uterine leiomyosarcoma.

Authors:  Jennifer A Ducie; Mario M Leitao
Journal:  Expert Rev Anticancer Ther       Date:  2015-11-26       Impact factor: 4.512

Review 9.  Current status of pulmonary metastasectomy from primary epithelial tumors.

Authors:  Tokujiro Yano; Fumihiro Shoji; Yoshihiko Maehara
Journal:  Surg Today       Date:  2009-02-07       Impact factor: 2.549

10.  Pulmonary metastasectomy in uterine malignancies: outcome and prognostic factors.

Authors:  Marco Anile; Sara Mantovani; Ylenia Pecoraro; Carolina Carillo; Lorenzo Gherzi; Andreina Pagini; Erino Angelo Rendina; Federico Venuta; Daniele Diso
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.